Skip Navigation


Nicotine & Tobacco Research Advance Access originally published online on August 28, 2009
Nicotine & Tobacco Research 2009 11(11):1265-1273; doi:10.1093/ntr/ntp136
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Article Summary
Right arrow All Versions of this Article:
11/11/1265    most recent
ntp136v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Oncken, C. A.
Right arrow Articles by Kranzler, H. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oncken, C. A.
Right arrow Articles by Kranzler, H. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?

Cheryl A. Oncken and H. R. Kranzler

Cheryl A. Oncken, M.D., M.P.H, Departments of Medicine and Obstetrics and Gynecology, University of Connecticut School of Medicine, Farmington, CT
H. R. Kranzler, M.D., Departments of Psychiatry and Genetics and Developmental Biology, University of Connecticut School of Medicine, Farmington, CT

Corresponding Author: Cheryl A. Oncken, M.D., M.P.H, Department of Medicine, MC 3940, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030-3940, USA. Telephone: 860-679-3425; Fax: 860-679-1250; E-mail: oncken{at}nso2.uchc.edu


  Abstract

Significance: Given the substantial health risks of smoking during pregnancy, and the potential of pharmacotherapy to enhance quit rates, a need exists to examine the utility of pharmacotherapy for smoking cessation during pregnancy.

Literature Review: We briefly review the first-line medications that are recommended for smoking cessation in nonpregnant adults. Additionally, we review the toxicity of tobacco smoke and the potential risks of pharmacotherapy as evidenced by animal studies. We review in more detail studies conducted in pregnant women, including (a) observational studies, (b) short-term safety and longer term uncontrolled studies, and (c) randomized controlled clinical trials (both effectiveness and efficacy studies).

Discussion: Because the safety and efficacy of pharmacotherapy for smoking cessation during pregnancy have not been established, no definitive recommendations can be made on the topic. Effectiveness trials have shown that nicotine replacement therapy (NRT) enhances smoking cessation during pregnancy, but efficacy trials have not shown an advantage for NRT compared with placebo treatment. Small sample size or poor medication compliance (with either the dose or the duration of treatment) may contribute to lack of efficacy in placebo-controlled NRT trials. However, these trials showed that NRT did not adversely affect birth outcomes and increased birth weight. Based on these findings and the fact that all medications have some risk, psychosocial interventions should be the first treatment option for pregnant smokers. Additional research is needed to determine fully the risks and benefits of the various pharmacotherapies for smoking cessation during pregnancy.

Received: December 18, 2008; Accepted: June 26, 2009
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.